Navigation Links
RiskMetrics Group (ISS) and Glass Lewis & Co. Support Nabi Biopharmaceuticals' Proposed Asset Sale
Date:10/30/2007

BOCA RATON, Fla., Oct. 30 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals (Nasdaq: NABI) (the "Company") announced today that RiskMetrics Group (ISS) and Glass Lewis & Co., two of the nation's leading independent proxy advisory firms, recommend that stockholders of the Company vote "FOR" the Company's proposed sale of its Biologics strategic business unit and certain Corporate Shared Services assets to Biotest Pharmaceuticals Corporation, a wholly owned subsidiary of Biotest AG, pursuant to an asset purchase agreement dated September 11, 2007. ISS and Glass Lewis provide voting advice to hundreds of institutional investors, mutual and pension funds and other fiduciaries.

"The recommendations of these two leading independent proxy advisory firms confirm our Board of Directors' unanimous view that the proposed asset sale is in the best interests of Nabi stockholders," said Dr. Leslie Hudson, Interim President and Chief Executive Officer of Nabi Biopharmaceuticals. "We urge all of our stockholders to vote "FOR" the proposed asset sale today."

Stockholders are encouraged to read the Company's definitive proxy materials in their entirety as they provide, among other things, a detailed discussion of the process that led to the proposed asset sale and reasons behind the Board of Directors' unanimous recommendation that stockholders vote "FOR" the proposed asset sale. Stockholders who have questions about the asset sale or need assistance in submitting their proxy or voting their shares should contact the Company's proxy solicitor, Morrow & Co., Inc., toll free at 1-800-662-5200.

The Company's special meeting of stockholders is scheduled for Thursday, November 8, 2007, at 10:00 a.m., local time, at the Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, Maryland. Stockholders of record at the close of business on October 10, 2007 are entitled to notice of and to vote at the special meeting.

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and, in certain areas, market products that target serious medical conditions in the areas of hepatitis and transplants, gram positive bacterial infections and nicotine addiction. We are a vertically integrated company with sales of antibodies and other biologics, including Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], a pipeline of products in various stages of development and a state-of-the-art manufacturing capability. The company operates through two strategic business units: Nabi Biologics and Nabi Pharmaceuticals. Nabi Biologics has responsibility for the company's protein and immunological products and development pipeline, including Nabi- HB. Nabi Pharmaceuticals is responsible for the NicVAX(R) (Nicotine Conjugate Vaccine) and StaphVAX(R) (Staphylococcus aureus Polysaccharide Conjugate Vaccine) development programs. For a complete list of pipeline products, please go to: http://www.nabi.com/pipeline/index.php. In September 2007, Nabi announced that it had entered into a definitive agreement with Biotest AG to sell the Nabi Biologics strategic business unit to Biotest Pharmaceuticals Corporation, including Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and other plasma business assets, including Nabi's state-of-the-art plasma protein production plant, and nine FDA-certified plasma collection centers across the U.S. The acquisition also will include certain of Nabi's Corporate Shared Services group assets and the company's Boca Raton, Florida headquarters and other facilities, as well as the assumption of certain liabilities, and is expected to close by the end of the year. The company is headquartered in Boca Raton, Florida. For additional information about Nabi Biopharmaceuticals, please visit our Web site: http://www.nabi.com.


'/>"/>
SOURCE Nabi Biopharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Cardinal Health likes growth potential of Viasys NeuroCare Group
2. Technology consulting group adds Sanders
3. CIO Leadership Series: Kathi Christian, QTI Group
4. CEO of healthcare group still hopeful IT will save employers money
5. California group says ruling weakens WARFs stem cell patent
6. Instant messaging comes to groups
7. Midwest plays small role in VC investment, angel groups to the rescue
8. Group promoting classified research elects officers
9. Milwaukee regional development group agrees on name
10. Local group building Dane County economic development corp.
11. Bruker AXS to acquire companies, form Microanalysis Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... -- Research and Markets has announced the addition ... Markets and Companies" to their offering. ... The number of ... past few years. More than 1,000 companies have been identified ... these are profiled in the report along with tabulation of ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... Safety Technology Consortium™ (SafeTEC™), $3 million in investment towards 15+ TEC Validation Projects™. ... and assays, and their applicability in drug safety assessment, for the industry as ...
(Date:1/16/2017)... ... January 16, 2017 , ... Appellate Court ... decision on the appeal filed by India-based Dishman Pharmaceutical & Chemical Ltd. company ... DPCL and one of its Dishman Group’s 100% wholly owned New Jersey-based subsidiary ...
(Date:1/14/2017)... Va. , Jan. 13, 2017  The Alliance ... statement in response to FDA final guidance ... for its continued leadership in emphasizing the importance of ... are keenly aware of the benefits biosimilars will bring ...   Yet the portion of the Guidance ...
Breaking Biology Technology:
(Date:1/6/2017)... -- Delta ID Inc., a leader in consumer-grade iris scanning ... CES® 2017. Delta ID has collaborated with Gentex Corporation ... of iris scanning as a secure, reliable and convenient ... car, and as a way to elevate the security ... ID and Gentex will demonstrate (booth #7326 LVCC) a ...
(Date:12/22/2016)... YORK , December 22, 2016 ... provider of secure solutions for the e-Government, Public Safety, HealthCare, and ... subsidiary of SuperCom, has been selected to implement and deploy a ... in Northern California , further expanding its presence ... ...
(Date:12/16/2016)... 16, 2016 Research and Markets has announced ... Global Forecast to 2021" report to their offering. ... The biometric vehicle access ... a CAGR of 14.06% from 2016 to 2021. The market is ... to reach 854.8 Million by 2021. The growth of the biometric ...
Breaking Biology News(10 mins):